These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11731185)

  • 1. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease.
    Vitale C; Fini M; Leonardo F; Rossini P; Cerquetani E; Onorati D; Rosano GM
    Maturitas; 2001 Dec; 40(3):239-45. PubMed ID: 11731185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of a sequential combination of estradiol valerate and cyproterone acetate on the functional properties of the arterial wall in menopausal women].
    Mares P; Dauzat M; Abramovici Y; Deklunder G; Body G; Crepin G; Denis A; Favier M
    Gynecol Obstet Fertil; 2000; 28(7-8):509-17. PubMed ID: 10996962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial.
    Gambacciani M; Monteleone P; Vitale C; Silvestri A; Fini M; Genazzani AR; Rosano GM
    Maturitas; 2002 Oct; 43(2):117-23. PubMed ID: 12385860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk.
    Silvestri A; Gambacciani M; Vitale C; Monteleone P; Ciaponi M; Fini M; Genazzani AR; Mercuro G; Rosano GM
    Maturitas; 2005 Apr; 50(4):305-11. PubMed ID: 15780531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
    Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
    J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance.
    Mares P; Dauzat M; Abramovici Y
    Maturitas; 2002 May; 42(1):45-53. PubMed ID: 12020979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate).
    Alwers R; Urdinola J; Onatra W; Sánchez F; Posso H
    Maturitas; 1999 May; 32(1):41-50. PubMed ID: 10423715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause.
    Polatti F; Capuzzo E; Viazzo F; Colleoni R; Abbiati I; Nappi RE
    Acta Obstet Gynecol Scand; 1999 Jan; 78(1):49-53. PubMed ID: 9926892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women.
    De Leo V; la Marca A; Orlandi R; Crippa D; Setacci C; Petraglia F
    Maturitas; 2003 Nov; 46(3):219-24. PubMed ID: 14585525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
    Schram JH; Boerrigter PJ; The TY
    Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study.
    Duvernoy CS; Rose PA; Kim HM; Kehrer C; Brook RD
    J Womens Health (Larchmt); 2007 Sep; 16(7):963-70. PubMed ID: 17903073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
    Saitta A; Altavilla D; Cucinotta D; Morabito N; Frisina N; Corrado F; D'Anna R; Lasco A; Squadrito G; Gaudio A; Cancellieri F; Arcoraci V; Squadrito F
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1512-9. PubMed ID: 11557681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.
    Cerquetani E; Vitale C; Mercuro G; Fini M; Zoncu S; Rosano GM
    Gynecol Endocrinol; 2004 Jun; 18(6):291-8. PubMed ID: 15497491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-alpha IVS1-397 C/C genotype and established coronary artery disease.
    Emre A; Sahin S; Erzik C; Nurkalem Z; Oz D; Cirakoglu B; Yesilcimen K; Ersek B
    Cardiology; 2006; 106(1):44-50. PubMed ID: 16612068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antiandrogens in hormone replacement therapy.
    Schneider HP
    Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
    Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM
    J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation.
    Koninckx PR; Lauweryns JM; Cornillie FJ
    Maturitas; 1993 Mar; 16(2):97-110. PubMed ID: 8387151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women.
    Sherwood A; Bower JK; McFetridge-Durdle J; Blumenthal JA; Newby LK; Hinderliter AL
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1782-7. PubMed ID: 17541023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT).
    McCarthy T; Dramusic V; Carter R; Costales A; Ratnam SS
    Maturitas; 1995 Jun; 22(1):13-23. PubMed ID: 7666812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.